United States Next-Generation Multiple Myeloma Therapies Market to hit US$ 37.07 Billion by 2033 | Top Companies - Takeda Pharmaceuticals, Amgen Inc., Bristol-Myers Squibb Company

"The global next-generation multiple myeloma therapies market size reached US$ 22.03 Billion in 2023 with a rise of US$ 23.13 Billion in 2024 and is expected to reach US$ 37.07 Billion by 2033, growing at a CAGR of 5.4% during the forecast period 2025-2033." As per DataM intelligence research report

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/next-generation-multiple-myeloma-therapies-market?sp

United States: Recent Industry Developments

✅ In October 2025, Bristol Myers Squibb (BMS) received FDA approval for its next-generation CAR-T therapy Abecma 2.0 for relapsed and refractory multiple myeloma. The updated therapy features enhanced T-cell persistence, improving patient response durability.

✅ In September 2025, Johnson & Johnson (Janssen Biotech) announced positive Phase III results for its bispecific antibody Tecvayli combined with Darzalex, showing superior progression-free survival in advanced multiple myeloma patients.

✅ In August 2025, Pfizer Inc. completed the acquisition of Autolus Therapeutics, expanding its cell and gene therapy pipeline targeting multiple myeloma and other hematologic malignancies. The deal strengthens Pfizer's oncology portfolio in next-gen immunotherapies.

✅ In July 2025, Gilead Sciences partnered with Arcellx Inc. to advance its ARC-SparX platform for controlled CAR-T activation, aiming to minimize toxicity and improve safety in multiple myeloma treatments.

Japan: Recent Industry Developments

✅ In October 2025, Takeda Pharmaceutical Co. initiated a Phase II clinical trial for its novel bispecific antibody TAK-573, targeting BCMA and CD3 for treatment-resistant multiple myeloma. The study focuses on improving efficacy in patients with poor prognostic profiles.

✅ In September 2025, Chugai Pharmaceutical (Roche Group Japan) developed an AI-assisted biomarker platform to identify patient subtypes responding best to BCMA-targeted therapies, enhancing personalized treatment strategies.

✅ In August 2025, Ono Pharmaceutical Co. Ltd. announced research collaboration with Kyoto University Hospital to explore next-generation T-cell engagers for relapsed multiple myeloma, emphasizing precision immunotherapy development.

✅ In July 2025, Daiichi Sankyo expanded its oncology research program to include next-gen antibody-drug conjugates (ADCs) targeting myeloma-specific antigens, aiming to reduce relapse rates and treatment resistance.

Next-Generation Multiple Myeloma Therapies Market: Drivers

The next-generation multiple myeloma Therapies market is advancing rapidly as breakthroughs in targeted therapies, immuno-oncology, and precision medicine transform disease management. Multiple myeloma, a complex blood cancer affecting plasma cells, is witnessing improved treatment outcomes through innovations such as CAR T-cell therapies, bispecific antibodies, and antibody-drug conjugates. These advanced modalities are offering durable responses even in relapsed and refractory patients. Rising incidence rates, growing diagnostic capabilities, and expanding clinical research pipelines are driving global market growth. Moreover, pharmaceutical companies are investing heavily in novel mechanisms of action to overcome drug resistance and enhance survival rates.

Technological progress in genomics, biomarker discovery, and personalized therapy design is accelerating the development of next-generation multiple myeloma treatments. Combination regimens involving immunotherapies and small-molecule inhibitors are becoming central to long-term disease control. The increasing number of FDA and EMA approvals for breakthrough therapies underscores strong regulatory and clinical momentum. Collaborations between biotech firms, academic institutions, and healthcare providers are fostering innovation and expanding access to advanced treatments. With the shift toward precision oncology and immune-based approaches, the next-generation multiple myeloma market is poised for transformative growth, offering renewed hope for patients worldwide.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/next-generation-multiple-myeloma-therapies-market?sp

Next-Generation Multiple Myeloma Therapies Market: Major Players

Takeda Pharmaceuticals, Inc., Amgen Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Sanofi, Karyopharm Therapeutics Inc., GSK plc. , Legend Biotech, Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals, Inc., among others.

Segment Covered in the Next-Generation Multiple Myeloma Therapies Market:

By Drug Class
The market is segmented into Monoclonal Antibodies, Immunomodulators, Proteasome Inhibitors, Bispecific Antibodies, CAR T-Cell Therapies, Antibody-Drug Conjugates, and Others. Monoclonal antibodies dominate the segment due to their proven efficacy and targeted action against cancer cells, while CAR T-cell therapies and bispecific antibodies are witnessing rapid growth driven by advancements in immuno-oncology.

By Route of Administration
Based on the route of administration, the market is categorized into Intravenous, Subcutaneous, and Oral. Intravenous administration leads the market owing to its widespread use in hospitals for high-dose delivery, whereas subcutaneous formulations are gaining traction for their convenience and potential for home-based treatment.

By Distribution Channel
The distribution network comprises Hospital Pharmacies and Retail Pharmacies. Hospital pharmacies hold the major share due to the administration of most therapies under clinical supervision, while retail pharmacies are expanding their role as supportive distribution channels for maintenance and follow-up treatments.

Research Process:

Both primary and secondary data sources have been used in the Next-Generation Multiple Myeloma Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Most Frequently Asked Questions in the Next-Generation Multiple Myeloma Therapies Market Research Industry:

➠ Who leads the Next-Generation Multiple Myeloma Therapies industry and what's their competitive positioning regarding capacity, performance, and profitability?
➠ What growth opportunities and market challenges do Next-Generation Multiple Myeloma Therapies market vendors face?
➠ Which segments show the highest growth potential and market share distribution?
➠ What factors are driving or limiting Next-Generation Multiple Myeloma Therapies market growth?
➠ What are the dominant sales and distribution strategies in the Next-Generation Multiple Myeloma Therapies industry?

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=next-generation-multiple-myeloma-therapies-market
(Purchase 2 or more Repots and get 50% Discount)

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sp

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.